2014-03-02 03:01 AM
SAN DIEGO--(BUSINESS WIRE)--Mar 1, 2014--For Media outside the U.S., Canada and UK
Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat R inhaler was effective and well tolerated in patients across asthma severities. These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego.
"Even with current treatment options, at least 40 percent of patients with asthma remain symptomatic, 1 which may put them at greater risk for exacerbations or asthma worsening" said Professor Pierluigi Paggiaro, Professor of Respiratory Medicine, University of Pisa, and lead author on the GraziaTinA-asthma R study. "It is important to investigate the efficacy and safety of new treatment options across different asthma severities."
The first results from the Phase III GraziaTinA-asthma R study were announced. The study demonstrated that tiotropium Respimat R improved lung function and was well tolerated in patients with asthma who remain symptomatic while receiving low-dose maintenance ICS treatment. 2
Also presented at the meeting was a new subset of data from the Phase III MezzoTinA-asthma R trials. The data showed that in patients with asthma who remained symptomatic while receiving moderate-dose maintenance ICS therapy, the addition of once-daily tiotropium reduced airflow obstruction independent of allergic status, as measured by the TH2 phenotype biomarker. 3
Finally, an analysis of a subset from the Phase III PrimoTinA-asthma R trials found the addition of once-daily tiotropium improved lung function responses independently of concomitant use of a leukotriene receptor antagonist (LTRA). This effect was demonstrated in patients with asthma who remained symptomatic despite receiving treatment with at least ICS/LABA. 4 Previous results from these pivotal, PrimoTinA-asthma R trials have shown that the addition of tiotropium Respimat R significantly increased time to first severe asthma exacerbation, as well as time to first episode of asthma worsening, compared with at least ICS/LABA therapy alone (current standard therapy). 5
NewsHome: An innovative resource for journalists
The Boehringer Ingelheim respiratory www.NewsHome.com is available and is the one-stop-shop for clear, concise and easy to understand information about asthma and other respiratory illnesses for the media.
For more detailed information please follow the links below:
About tiotropium Respimat R in asthma factsheet: http://bit.ly/NqNjfv
To access the full abstracts please follow the link: http://bit.ly/1jh3AyF
To view the 'notes to editors' and 'references': ?http://bit.ly/1cUhMfl
* Please note: Tiotropium Respimat R is currently NOT APPROVED for use in asthma, except in Colombia. Tiotropium's safety and efficacy have not yet been fully established in asthma.
? Inhaled corticosteroid
? Long-acting beta2-agonists
CONTACT: Boehringer Ingelheim
Phone: +49 6132 77 3519
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Boehringer Ingelheim
Copyright Business Wire 2014
PUB: 03/01/2014 12:45 PM/DISC: 03/01/2014 12:45 PM